In 2023, the synthetic biology and alternative protein sectors continued to attract significant attention from investors, with a total of 10 related companies securing investments to enhance the depth and breadth of their supply chain capabilities. Additionally, the domestic probiotics sector experienced three rounds of investment and financing this year. With the continuous growth of research capabilities in domestic probiotic research institutions, venture capital firms hold high expectations for this sector.
Most of the financing stages for companies in the synthetic biology field are in the early stages. Among the 10 companies surveyed, three received angel round financing, four received Series A financing, and one received Pre-A round financing, indicating that most companies in the synthetic biology field are in the early stages of research and development. Alternative proteins emerged as a major fundraising track in 2023, with seven alternative protein companies securing financing. Notably, six of these companies are closely aligned with synthetic biology. (Source: New Business Industry)
Sign Up to Receive China Updates Weekly Newsletter for FREE, HERE
Visit HPA-China’s Information Hub, HERE